FindMyKOL

Indira Brar, MD

Basic profile

Henry Ford Health

ORCIDOn fileNPIOn fileSign in to see identifiers
✓ Itemized record
RegionDetroit, MI · MidwestSpecialtyInfectious DiseaseFocusInfectious Disease
Active KOLFindMyKOL type: NationalLatest publicationSee ScholarshipOnline presenceNot yet checkedPayments2021 onwardNIH fundingNot yet indexedWhy? →

Indira Brar is an Infectious Disease physician affiliated with Henry Ford Health. OpenAlex indexes 134 publications with 4,127 citations (h-index 23); ClinicalTrials.gov lists 1 registered study matched to this name.

Overview

Scholarship

indexed output and impact (OpenAlex)
134publications

Publications indexed by OpenAlex, matched via ORCID. Counts exclude supporting files.

4,127citations

Citations across these publications.

23h-index

H-index from these publications.

Clinical & industry

trials, payments and federal funding
1clinical trials

Investigator role on registered studies.

View trials ↓
9companies · 2021 onward

Companies reporting payments to CMS. Facts, not judgments.

View payments ↓

Clinical trials

Registered studies on ClinicalTrials.gov where the overall official or a site investigator name-matches this physician, confirmed against known institution/geography. Latest few shown; the full list is part of the full profile.

Industry payments

9 companies reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:

  • Gilead Sciences, Inc.
    Program year202546 payments
    $41,300
  • Gilead
    Program year20258 paymentsResearch
    $20,467
  • ViiV Healthcare Company
    Program year202526 payments
    $16,726
All 37 payment records: search, sort and filter.Explore →

Payment records matched to this physician's NPI in CMS Open Payments, program years 2021 onward. Research funding is listed under each investigator the record names.

Medicare prescribing footprint (2023)

The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.

  • Anti-infectives

    79.6%
    Protease Inhibitor26%
    Prezista33%Symtuza26%Prezcobix20%Ritonavir19%Atazanavir Sulfate3%
    Part D<11 patients
    Human Immunodeficiency Virus Integrase Strand Transfer Inhibitor16.9%
    Tivicay58%Isentress12%Isentress Hd11%Dovato10%Juluca9%
    Part D<11 patients

    + 10 more classes in this area

  • Cardiovascular

    4.1%
    Statin2.7%
    Atorvastatin Calcium100%
    Part D≥13 patients
    Aldosterone antagonist (MRA)0.7%
    Spironolactone100%
    Part D<11 patients

    + 1 more class in this area

  • Respiratory

    3.8%
    Corticosteroid1.4%
    Flunisolide50%Fluticasone Propionate50%
    Part D<11 patients
    Opioid Agonist1.4%
    Hydrocodone-Acetaminophen100%
    Part D<11 patients

    + 1 more class in this area

Where care is delivered (Part B)38.4% facility · 61.6% office

Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.

Similar KOLs

Other experts from the same institution or the same specialty.

A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments, shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet. Reviewed account links and congress post links can appear separately. Absence of a section means “not yet looked,” never “none found.”